Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

T-cell acute lymphoblastic leukemia in patients 1-45 years treated with the pediatric NOPHO ALL2008 protocol

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Quist-Paulsen, P, Toft, N, Heyman, M, Abrahamsson, J, Griškevičius, L, Hallböök, H, Jónsson, ÓG, Palk, K, Vaitkeviciene, G, Vettenranta, K, Åsberg, A, Frandsen, TL, Opdahl, S, Marquart, HV, Siitonen, S, Osnes, LT, Hultdin, M, Overgaard, UM, Wartiovaara-Kautto, U & Schmiegelow, K 2020, 'T-cell acute lymphoblastic leukemia in patients 1-45 years treated with the pediatric NOPHO ALL2008 protocol' Leukemia, bind 34, nr. 2, s. 347-357. https://doi.org/10.1038/s41375-019-0598-2

APA

Quist-Paulsen, P., Toft, N., Heyman, M., Abrahamsson, J., Griškevičius, L., Hallböök, H., ... Schmiegelow, K. (2020). T-cell acute lymphoblastic leukemia in patients 1-45 years treated with the pediatric NOPHO ALL2008 protocol. Leukemia, 34(2), 347-357. https://doi.org/10.1038/s41375-019-0598-2

CBE

Quist-Paulsen P, Toft N, Heyman M, Abrahamsson J, Griškevičius L, Hallböök H, Jónsson ÓG, Palk K, Vaitkeviciene G, Vettenranta K, Åsberg A, Frandsen TL, Opdahl S, Marquart HV, Siitonen S, Osnes LT, Hultdin M, Overgaard UM, Wartiovaara-Kautto U, Schmiegelow K. 2020. T-cell acute lymphoblastic leukemia in patients 1-45 years treated with the pediatric NOPHO ALL2008 protocol. Leukemia. 34(2):347-357. https://doi.org/10.1038/s41375-019-0598-2

MLA

Vancouver

Quist-Paulsen P, Toft N, Heyman M, Abrahamsson J, Griškevičius L, Hallböök H o.a. T-cell acute lymphoblastic leukemia in patients 1-45 years treated with the pediatric NOPHO ALL2008 protocol. Leukemia. 2020 feb;34(2):347-357. https://doi.org/10.1038/s41375-019-0598-2

Author

Quist-Paulsen, P ; Toft, N ; Heyman, M ; Abrahamsson, J ; Griškevičius, L ; Hallböök, H ; Jónsson, Ó G ; Palk, K ; Vaitkeviciene, G ; Vettenranta, K ; Åsberg, A ; Frandsen, T L ; Opdahl, S ; Marquart, H V ; Siitonen, S ; Osnes, L T ; Hultdin, M ; Overgaard, U M ; Wartiovaara-Kautto, U ; Schmiegelow, K. / T-cell acute lymphoblastic leukemia in patients 1-45 years treated with the pediatric NOPHO ALL2008 protocol. I: Leukemia. 2020 ; Bind 34, Nr. 2. s. 347-357.

Bibtex

@article{a2aea9df79e3433d85eb61caff1667bf,
title = "T-cell acute lymphoblastic leukemia in patients 1-45 years treated with the pediatric NOPHO ALL2008 protocol",
abstract = "The NOPHO ALL2008 is a population-based study using an unmodified pediatric protocol in patients 1-45 years of age with acute lymphoblastic leukemia. Patients with T-ALL were given a traditional pediatric scheme if fast responding (minimal residual disease (MRD) < 0.1{\%} day 29), or intensive block-based chemotherapy if slow responding (MRD > 0.1{\%} day 29). Both treatment arms included pediatric doses of high-dose methotrexate and asparaginase. If MRD ≥ 5{\%} on day 29 or ≥0.1{\%} after consolidation, patients were assigned to allogeneic hematopoietic stem cell transplantation. The 5-year overall survival of the 278 T-ALL patients was 0.75 (95{\%} CI 0.69-0.81), being 0.82 (0.74-0.88) for patients 1.0-9.9 years, 0.76 (0.66-0.86) for those 10.0-17.9 years, and 0.65 (0.55-0.75) for the older patients. The risk of death in first remission was significantly higher in adults (12{\%}) compared with the 1-9 years group (4{\%}). The MRD responses in the three age groups were similar, and only a nonsignificant increase in relapse risk was found in adults. In conclusion, an unmodified pediatric protocol in patients 1-45 years is effective in all age groups. The traditional pediatric treatment schedule was safe for all patients, but the intensive block therapy led to a high toxic death rate in adults.",
author = "P Quist-Paulsen and N Toft and M Heyman and J Abrahamsson and L Griškevičius and H Hallb{\"o}{\"o}k and J{\'o}nsson, {{\'O} G} and K Palk and G Vaitkeviciene and K Vettenranta and A {\AA}sberg and Frandsen, {T L} and S Opdahl and Marquart, {H V} and S Siitonen and Osnes, {L T} and M Hultdin and Overgaard, {U M} and U Wartiovaara-Kautto and K Schmiegelow",
year = "2020",
month = "2",
doi = "10.1038/s41375-019-0598-2",
language = "English",
volume = "34",
pages = "347--357",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "2",

}

RIS

TY - JOUR

T1 - T-cell acute lymphoblastic leukemia in patients 1-45 years treated with the pediatric NOPHO ALL2008 protocol

AU - Quist-Paulsen, P

AU - Toft, N

AU - Heyman, M

AU - Abrahamsson, J

AU - Griškevičius, L

AU - Hallböök, H

AU - Jónsson, Ó G

AU - Palk, K

AU - Vaitkeviciene, G

AU - Vettenranta, K

AU - Åsberg, A

AU - Frandsen, T L

AU - Opdahl, S

AU - Marquart, H V

AU - Siitonen, S

AU - Osnes, L T

AU - Hultdin, M

AU - Overgaard, U M

AU - Wartiovaara-Kautto, U

AU - Schmiegelow, K

PY - 2020/2

Y1 - 2020/2

N2 - The NOPHO ALL2008 is a population-based study using an unmodified pediatric protocol in patients 1-45 years of age with acute lymphoblastic leukemia. Patients with T-ALL were given a traditional pediatric scheme if fast responding (minimal residual disease (MRD) < 0.1% day 29), or intensive block-based chemotherapy if slow responding (MRD > 0.1% day 29). Both treatment arms included pediatric doses of high-dose methotrexate and asparaginase. If MRD ≥ 5% on day 29 or ≥0.1% after consolidation, patients were assigned to allogeneic hematopoietic stem cell transplantation. The 5-year overall survival of the 278 T-ALL patients was 0.75 (95% CI 0.69-0.81), being 0.82 (0.74-0.88) for patients 1.0-9.9 years, 0.76 (0.66-0.86) for those 10.0-17.9 years, and 0.65 (0.55-0.75) for the older patients. The risk of death in first remission was significantly higher in adults (12%) compared with the 1-9 years group (4%). The MRD responses in the three age groups were similar, and only a nonsignificant increase in relapse risk was found in adults. In conclusion, an unmodified pediatric protocol in patients 1-45 years is effective in all age groups. The traditional pediatric treatment schedule was safe for all patients, but the intensive block therapy led to a high toxic death rate in adults.

AB - The NOPHO ALL2008 is a population-based study using an unmodified pediatric protocol in patients 1-45 years of age with acute lymphoblastic leukemia. Patients with T-ALL were given a traditional pediatric scheme if fast responding (minimal residual disease (MRD) < 0.1% day 29), or intensive block-based chemotherapy if slow responding (MRD > 0.1% day 29). Both treatment arms included pediatric doses of high-dose methotrexate and asparaginase. If MRD ≥ 5% on day 29 or ≥0.1% after consolidation, patients were assigned to allogeneic hematopoietic stem cell transplantation. The 5-year overall survival of the 278 T-ALL patients was 0.75 (95% CI 0.69-0.81), being 0.82 (0.74-0.88) for patients 1.0-9.9 years, 0.76 (0.66-0.86) for those 10.0-17.9 years, and 0.65 (0.55-0.75) for the older patients. The risk of death in first remission was significantly higher in adults (12%) compared with the 1-9 years group (4%). The MRD responses in the three age groups were similar, and only a nonsignificant increase in relapse risk was found in adults. In conclusion, an unmodified pediatric protocol in patients 1-45 years is effective in all age groups. The traditional pediatric treatment schedule was safe for all patients, but the intensive block therapy led to a high toxic death rate in adults.

U2 - 10.1038/s41375-019-0598-2

DO - 10.1038/s41375-019-0598-2

M3 - Journal article

VL - 34

SP - 347

EP - 357

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 2

ER -

ID: 59004656